Life sciences investment in Kenya spans healthcare facilities, pharmaceutical manufacturing, biotechnology and health data analytics, each governed by its own regulatory pathway. The sector is attracting international interest, drawn by the size of the East African market, Nairobi’s position as a regional hub and policy support for local pharmaceutical manufacturing. This guide sets out the main legal touchpoints an investor should map before committing capital.
Investment Structures for Life Sciences Investment in Kenya
Private hospitals and health facilities can be structured as Kenyan private limited companies with foreign shareholders. Section 89 of the Health Act, 2017 permits private entities to operate hospitals, clinics, laboratories and other health sector institutions, subject to licensing by the appropriate regulatory bodies, and the standards for an operational licence are set in regulations made by the Cabinet Secretary. Licences are issued to the operating entity, so any life sciences investment in Kenya should settle its structure must be settled before applications are filed. Facility licensing is covered in our guide to healthcare regulation in Kenya.
For a life sciences investment in Kenya with a public element, the Public Private Partnerships Act, 2021 provides a structured mechanism for investor and government partnerships and repealed the Public Private Partnerships Act, 2013 (section 93). A partnership is the appropriate route where the investment involves a public facility, public land or a long-term concession alongside the public system. A purely private greenfield facility can generally proceed through ordinary incorporation and licensing.
Pharmaceutical manufacturing needs, in addition to incorporation, the Pharmacy and Poisons Board licences contemplated by the Pharmacy and Poisons Act (Cap 244), whose section 3A empowers the Board to grant or withdraw licences to manufacturers and marketing authorisation for medical products. Products are registered under the Registration of Health Products and Technologies Rules, 2022, and the application must include a manufacturing licence and good manufacturing practice certificate where applicable. Plan the order of licence and registration filings accordingly. See our guides to pharmaceutical regulation in Kenya and medical devices regulation.
Biotechnology and GMO Regulation
The Biosafety Act, 2009 regulates activities involving genetically modified organisms and establishes the National Biosafety Authority. Part III provides for separate applications for contained use (section 18), introduction into the environment (section 19), importation (section 20) and placing on the market (section 21), with risk assessment under section 27. Each activity needs its own approval, so a research programme and a commercial product will follow different application paths. GMO policy has also shifted over time, so investors should obtain a current assessment before committing capital to a GMO-dependent model.
Health Data and Research Governance
Research involving human subjects and health data engages several overlapping frameworks: the Data Protection Act, 2019, ethics review, and research licensing by the National Commission for Science, Technology and Innovation under the Science, Technology and Innovation Act, 2013.
The Data Protection Act defines “sensitive personal data” to include health status and genetic data, and section 44 bars processing of sensitive personal data unless the Act’s conditions are met. Section 31 requires a data protection impact assessment before processing that is likely to result in high risk to data subjects, and section 48 sets conditions for transferring personal data out of Kenya, including proof of appropriate safeguards to the Data Commissioner. Investors in clinical research or health analytics should confirm early whether the model involves cross-border transfers.
Intellectual Property in Life Sciences
Patents are the primary protection for pharmaceutical and biotechnology innovation, governed by the Industrial Property Act, 2001 and administered by the Kenya Industrial Property Institute. Under section 60 a patent expires twenty years from the filing date, and section 61 requires an annual fee to maintain the application or patent.
Section 58(2) provides that patent rights do not extend to articles put on the market in Kenya or in any other country by the owner or with the owner’s consent, which supports parallel importation. Sections 72 to 77 deal with compulsory licences, including for non-working. Kenya does not appear on the WTO list of least-developed countries, so investors should not assume LDC-specific transition arrangements apply, and should take specific advice before building a generics or biosimilars strategy around any flexibility.
Tax, Incentives and Employment
The Special Economic Zones Act, 2015 provides a framework for zone incentives, and goods in a designated zone are generally regarded as outside the customs territory for import duty purposes. The incentive package available depends on the scale, location and structure of the investment and the current tax legislation, so confirm it at the structuring stage rather than retrofitting it later.
Life sciences employers are subject to the Employment Act, 2007 like any other employer, with an additional layer of professional registration for clinical staff. Foreign clinicians and researchers typically need registration or a practising licence from the relevant professional regulator in addition to a work permit, and the professional step is often the longer of the two.
Due Diligence on Existing Facilities and Businesses
Investors acquiring an existing hospital, clinic, pharmacy or distribution business should treat licence transferability as a primary diligence item. Because licences are issued to a specific legal entity, confirm licence by licence whether the acquisition structure preserves them or whether fresh applications are needed, since a gap between completion and re-licensing can leave the business unable to operate lawfully. Diligence should also cover historical compliance with the Data Protection Act where the target holds patient records, because prior non-compliance can expose the investor to enforcement after completion.
How We Can Help
Clay & Associates Advocates advises on every stage of life sciences investment in Kenya, including structuring, licensing sequencing, due diligence and regulatory strategy for life sciences ventures in Kenya. Our life sciences and healthcare practice brings these workstreams together, and you can contact us to discuss your investment before licence applications are filed.
Sources: Health Act, 2017, section 89; Public Private Partnerships Act, 2021; Pharmacy and Poisons Act (Cap 244); Registration of Health Products and Technologies Rules, 2022; Biosafety Act, 2009; Science, Technology and Innovation Act, 2013; Data Protection Act, 2019; Industrial Property Act, 2001; Special Economic Zones Act, 2015; Employment Act, 2007; WTO, Least-developed countries.
Frequently asked questions
Can foreigners own a private hospital in Kenya?
The Health Act permits private entities to operate hospitals and clinics, subject to licensing by the appropriate regulatory bodies. We are not aware of a blanket ban on foreign shareholding, but licences are issued to the operating entity and must be obtained before it operates.
Do GMO activities need separate approvals?
Yes. The Biosafety Act provides separate applications for contained use, introduction into the environment, importation and placing on the market.
How long does a Kenyan patent last?
Twenty years from the filing date under section 60 of the Industrial Property Act, subject to payment of annual fees.
Is health data treated differently under Kenyan law?
Yes. Health status and genetic data are sensitive personal data under the Data Protection Act, with stricter conditions for processing and a duty to carry out an impact assessment where processing is high risk.
Need advice on your own matter?
Tell us what you are dealing with. You will know what it involves and what it costs before you commit.
This article is general information on Kenyan law as at its publication date, not legal advice. Reading it does not create an advocate and client relationship.
